Tae Woo Park1,2, Marc R Larochelle2,3, Richard Saitz2,3,4, Na Wang5, Dana Bernson6, Alexander Y Walley2,3. 1. Department of Psychiatry, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA. 2. Grayken Center for Addiction, Boston Medical Center, Boston, MA, USA. 3. Department of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education (CARE) Unit, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA. 4. Department of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA. 5. Biostatistics, Epidemiology, and Data Analytics Center, Boston University School of Public Health, Boston, MA, USA. 6. Office of Population Health, Massachusetts Department of Public Health, Boston, MA, USA.
Abstract
BACKGROUND AND AIMS: Benzodiazepines are commonly prescribed to patients with opioid use disorder receiving buprenorphine treatment, yet may increase overdose risk. However, prescribed benzodiazepines may improve retention in care by reducing buprenorphine discontinuation and thus may prevent relapse to illicit opioid use. We aimed to test the association between benzodiazepine prescription and fatal opioid overdose, non-fatal opioid overdose, all-cause mortality and buprenorphine discontinuation. DESIGN AND SETTING: This was a retrospective cohort study using five individually linked data sets from Massachusetts, United States government agencies. PARTICIPANTS: We studied 63 389 Massachusetts residents aged 18 years or older who received buprenorphine treatment between January 2012 and December 2015. MEASUREMENTS: Filled benzodiazepine prescription during buprenorphine treatment was the main independent variable. The primary outcome was time to fatal opioid overdose. Secondary outcomes were time to non-fatal opioid overdose, all-cause mortality and buprenorphine discontinuation. We defined buprenorphine discontinuation as having a 30-day gap without another prescription following the end date of the previous prescription. We used Cox proportional hazards models to calculate hazards ratios that tested the association between receipt of benzodiazepines and all outcomes, restricted to periods during buprenorphine treatment. FINDINGS: Of the 63 345 individuals who received buprenorphine, 24% filled at least one benzodiazepine prescription during buprenorphine treatment. Thirty-one per cent of the 183 deaths from opioid overdose occurred when individuals received benzodiazepines during buprenorphine treatment. Benzodiazepine receipt during buprenorphine treatment was associated with an increased risk of fatal opioid overdose adjusted hazard ratio (HR) = 2.92, 95% confidence interval (CI) = 2.10-4.06, non-fatal opioid overdose, adjusted HR = 2.05, 95% CI, 1.68-2.50, all-cause mortality, adjusted HR = 1.90, 95% CI, 1.48-2.44 and a decreased risk of buprenorphine discontinuation, adjusted HR = 0.87, 95% CI, 0.85-0.89. CONCLUSIONS: Benzodiazepine receipt appears to be associated with both increased risk of opioid overdose and all-cause mortality and decreased risk of buprenorphine discontinuation among people receiving buprenorphine.
BACKGROUND AND AIMS: Benzodiazepines are commonly prescribed to patients with opioid use disorder receiving buprenorphine treatment, yet may increase overdose risk. However, prescribed benzodiazepines may improve retention in care by reducing buprenorphine discontinuation and thus may prevent relapse to illicit opioid use. We aimed to test the association between benzodiazepine prescription and fatal opioid overdose, non-fatal opioid overdose, all-cause mortality and buprenorphine discontinuation. DESIGN AND SETTING: This was a retrospective cohort study using five individually linked data sets from Massachusetts, United States government agencies. PARTICIPANTS: We studied 63 389 Massachusetts residents aged 18 years or older who received buprenorphine treatment between January 2012 and December 2015. MEASUREMENTS: Filled benzodiazepine prescription during buprenorphine treatment was the main independent variable. The primary outcome was time to fatal opioid overdose. Secondary outcomes were time to non-fatal opioid overdose, all-cause mortality and buprenorphine discontinuation. We defined buprenorphine discontinuation as having a 30-day gap without another prescription following the end date of the previous prescription. We used Cox proportional hazards models to calculate hazards ratios that tested the association between receipt of benzodiazepines and all outcomes, restricted to periods during buprenorphine treatment. FINDINGS: Of the 63 345 individuals who received buprenorphine, 24% filled at least one benzodiazepine prescription during buprenorphine treatment. Thirty-one per cent of the 183 deaths from opioid overdose occurred when individuals received benzodiazepines during buprenorphine treatment. Benzodiazepine receipt during buprenorphine treatment was associated with an increased risk of fatal opioid overdose adjusted hazard ratio (HR) = 2.92, 95% confidence interval (CI) = 2.10-4.06, non-fatal opioid overdose, adjusted HR = 2.05, 95% CI, 1.68-2.50, all-cause mortality, adjusted HR = 1.90, 95% CI, 1.48-2.44 and a decreased risk of buprenorphine discontinuation, adjusted HR = 0.87, 95% CI, 0.85-0.89. CONCLUSIONS:Benzodiazepine receipt appears to be associated with both increased risk of opioid overdose and all-cause mortality and decreased risk of buprenorphine discontinuation among people receiving buprenorphine.
Authors: Ulrike Willinger; Elisabeth Lenzinger; Kurt Hornik; Gabriele Fischer; Georg Schönbeck; Harald N Aschauer; Kurt Meszaros Journal: Alcohol Alcohol Date: 2002 Nov-Dec Impact factor: 2.826
Authors: Kevin Y Xu; Jacob T Borodovsky; Ned Presnall; Carrie M Mintz; Sarah M Hartz; Laura J Bierut; Richard A Grucza Journal: Am J Psychiatry Date: 2021-03-03 Impact factor: 19.242
Authors: April M Young; Jennifer L Brown; Timothy Hunt; Linda S Sprague Martinez; Redonna Chandler; Emmanuel Oga; T John Winhusen; Trevor Baker; Tracy Battaglia; Rachel Bowers-Sword; Amy Button; Amanda Fallin-Bennett; Laura Fanucchi; Patricia Freeman; LaShawn M Glasgow; Jennifer Gulley; Charles Kendell; Michelle Lofwall; Michael S Lyons; Maria Quinn; Bruce David Rapkin; Hilary L Surratt; Sharon L Walsh Journal: BMJ Open Date: 2022-09-19 Impact factor: 3.006
Authors: Traci H Abraham; Lakiesha Kemp; Penny White; Kathy Marchant; Hildi J Hagedorn; Keith Humphreys; Michael A Cucciare Journal: J Med Internet Res Date: 2022-09-19 Impact factor: 7.076
Authors: Julie M Donohue; Marian P Jarlenski; Joo Yeon Kim; Lu Tang; Katherine Ahrens; Lindsay Allen; Anna Austin; Andrew J Barnes; Marguerite Burns; Chung-Chou H Chang; Sarah Clark; Evan Cole; Dushka Crane; Peter Cunningham; David Idala; Stefanie Junker; Paul Lanier; Rachel Mauk; Mary Joan McDuffie; Shamis Mohamoud; Nathan Pauly; Logan Sheets; Jeffery Talbert; Kara Zivin; Adam J Gordon; Susan Kennedy Journal: JAMA Date: 2021-07-13 Impact factor: 56.272